Progressive supranuclear palsy (PSP) - Epidemiology Forecast-2030

Progressive supranuclear palsy (PSP) - Epidemiology Forecast-2030

  • April 2020 •
  • 80 pages •
  • Report ID: 5879445 •
  • Format: PDF
Progressive supranuclear palsy (PSP) - Epidemiology Forecast-2030 report delivers an in-depth understanding of the disease, historical & forecasted epidemiology of Progressive supranuclear palsy in the United States, EU5 (Germany, Spain, Italy, France and United Kingdom) and Japan.

Geography Covered
• The United States
• EU5 (Germany, France, Italy, Spain and the United Kingdom)
• Japan
Study Period: 2017-2030

Progressive supranuclear palsy Disease Understanding
Progressive Supranuclear Palsy (PSP) is an adult onset, progressive, sporadic neurodegenerative disease and an important cause of atypical Parkinsonism. The classic syndrome of PSP (Richardson’s syndrome or RS) is characterized by postural instability and falls early in the disease course and by gaze dysfunction affecting the vertical eye movements more than the horizontal ones.

Progressive supranuclear palsy Epidemiology
The Progressive supranuclear palsy epidemiology division provide the insights about historical and current patient pool and forecasted trend for every 7 major countries. The epidemiology data for Progressive supranuclear palsy are studied through all possible division to give a better understanding about the Disease scenario in 7MM. It also helps to recognize the causes of current and forecasted trends by exploring numerous studies, survey reports and views of key opinion leaders.
Progressive supranuclear palsy Epidemiology Segmentation
The disease epidemiology covered in the report provides historical as well as forecasted epidemiology (Prevalence of Progressive supranuclear palsy, Phenotype associated with Progressive supranuclear palsy, Gender specific Prevalence of Progressive supranuclear palsy, Comorbidities associated with Progressive supranuclear palsy) scenario of Progressive supranuclear palsy in the 7MM covering United States, EU5 countries (Germany, Spain, Italy, France and United Kingdom) and Japan from 2017-2030.
The report also provides the epidemiology trends observed in the 7MM during the study period, along with the assumptions undertaken. The calculated data are presented with relevant tables and graphs to give a clear view of the epidemiology at first sight.
According to the report estimates, there were 98,498 cases of Progressive supranuclear palsy in 7MM in 2017.

Report Scope
• The report covers detailed overview of Progressive supranuclear palsy explaining its causes, symptoms, classification, pathophysiology, diagnosis and treatment patterns
• The report provides the insight about the historical and forecasted patient pool of Progressive supranuclear palsy in 7 major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK) and Japan
• The Report assesses the disease risk and burden and highlights the unmet needs of the disease
• The Report helps to recognize the growth opportunities in the 7MM with respect to the patient population
• The report provides the segmentation of the disease epidemiology by prevalence of Progressive supranuclear palsy, phenotype associated with Progressive supranuclear palsy, gender specific prevalence of Progressive supranuclear palsy, comorbidities associated with Progressive supranuclear palsy

Key strengths
• 11 Years Forecast
• 7MM Coverage
• Epidemiology Segmentation
• Key Cross Competition
• Market Size by Therapies

• Drugs Uptake


Key assessments
• Pipeline Product Profiles
• Key Products and Key Players
• Market Drivers and Barriers